Related references
Note: Only part of the references are listed.p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib (vol 55, pg 98, 2016
Mohammad Krayem et al.
EUROPEAN JOURNAL OF CANCER (2022)
Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence
Philip C. Mueller et al.
PHARMACOLOGY (2021)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
Paola Menichini et al.
CELLS (2021)
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)
Thomas Cluzeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals
Stephen L. Abrams et al.
CELLS (2021)
SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status
Kenji M. Fujihara et al.
MOLECULAR CANCER THERAPEUTICS (2021)
TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment
Martino Maddalena et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells
Luisa Klemke et al.
FRONTIERS IN ONCOLOGY (2021)
Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelody-splastic syndromes and acute myeloid leukemia
Nabih Maslah et al.
HAEMATOLOGICA (2020)
TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer
Shaw M. Akula et al.
AGING-US (2020)
Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
William H. Chappell et al.
AGING-US (2020)
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer
Luisa F. Escobar-Hoyos et al.
CANCER CELL (2020)
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Yunzhen Qian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development
Michele Stanchina et al.
CANCERS (2020)
ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
Shigeru Hashimoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study
Yutaka Endo et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2019)
Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment
Ning Pu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation
Zhi-Xian Yin et al.
ONCOTARGET (2018)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Qiang Zhang et al.
CELL DEATH & DISEASE (2018)
Contemporary Management of Localized Resectable Pancreatic Cancer
Anuhya Kommalapati et al.
CANCERS (2018)
Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies
Alette Ruarus et al.
CANCERS (2018)
The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
Naoise C. Synnott et al.
TRANSLATIONAL ONCOLOGY (2018)
Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
Lena Haffo et al.
SCIENTIFIC REPORTS (2018)
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lauren Y. Lee et al.
BLOOD (2017)
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
Anne Perdrix et al.
CANCERS (2017)
Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14
Yongxing Du et al.
CANCER RESEARCH (2017)
An open-label phase I dose-finding study of APR-246 in hematological malignancies
S. Deneberg et al.
BLOOD CANCER JOURNAL (2016)
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
Asa Fransson et al.
JOURNAL OF OVARIAN RESEARCH (2016)
Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
Vladimir J. N. Bykov et al.
FRONTIERS IN ONCOLOGY (2016)
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing
Alexander J. Cole et al.
SCIENTIFIC REPORTS (2016)
p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
Mohammad Krayem et al.
EUROPEAN JOURNAL OF CANCER (2016)
BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy
Jose Manuel Bravo-San Pedro et al.
AUTOPHAGY (2015)
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
Xi Wang et al.
CELLULAR SIGNALLING (2015)
APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma
David S. H. Liu et al.
GUT (2015)
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
N. Mohell et al.
CELL DEATH & DISEASE (2015)
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Susann Weissmueller et al.
CELL (2014)
Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells
Melissa Sokolosky et al.
CELL CYCLE (2014)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors
Brooke M. Emerling et al.
CELL (2013)
Pancreatic cancer: A comprehensive review and update
Thiruvengadam Muniraj et al.
DM DISEASE-A-MONTH (2013)
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance
Katia Meirelles et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Involvement of Akt and mTOR in chemotherapeutic and hormonal-based drug resistance and response to radiation in breast cancer cells
Linda S. Steelman et al.
CELL CYCLE (2011)
PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
Roza Zandi et al.
CLINICAL CANCER RESEARCH (2011)
PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73
N. Rokaeus et al.
ONCOGENE (2010)
Phenotype and Genotype of Pancreatic Cancer Cell Lines
Emily L. Deer et al.
PANCREAS (2010)
The EGFR-GEP100-Arf6-AMAP1 Signaling Pathway Specific to Breast Cancer Invasion and Metastasis†
Hisataka Sabe et al.
TRAFFIC (2009)
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance
J. A. McCubrey et al.
LEUKEMIA (2008)
A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells
Brian D. Lehmann et al.
CELL CYCLE (2007)
AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells
JJ Zhu et al.
CANCER GENETICS AND CYTOGENETICS (2005)
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database
VJN Bykov et al.
CARCINOGENESIS (2002)
p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells
YH Choi et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2000)
Share Paper
